{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T21:04:10Z","timestamp":1771707850293,"version":"3.50.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clgc.2025.102489","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T23:22:56Z","timestamp":1766272976000},"page":"102489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integral Approach in the Follow-up of Prostate Cancer Patients: SOGUG Multidisciplinary Expert Panel Insights"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7460-1859","authenticated-orcid":false,"given":"Mar\u00eda Jos\u00e9","family":"M\u00e9ndez-Vidal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"G\u00f3mez de Iturriaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"L\u00f3pez Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Mart\u00ednez Ballesteros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Ruiz Vozmediano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ar\u00e1nzazu","family":"Gonz\u00e1lez-del-Alba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Mu\u00f1oz-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10437","key":"10.1016\/j.clgc.2025.102489_bib0001","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clgc.2025.102489_bib0002","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s11523-022-00925-7","article-title":"Addressing challenges and controversies in the management of prostate cancer with multidisciplinary teams","volume":"17","author":"Shore","year":"2022","journal-title":"Target Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2025.102489_bib0003","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102489_bib0004","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102489_bib0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102489_bib0006","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102489_bib0007","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN Guidelines\u00ae insights. Prostate Cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.clgc.2025.102489_bib0008","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncpuro0995","article-title":"Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?","volume":"5","author":"Higano","year":"2008","journal-title":"Nat Clin Pract Urol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102489_bib0009","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","article-title":"Skeletal fractures negatively correlate with overall survival in men with prostate cancer","volume":"168","author":"Oefelein","year":"2002","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.clgc.2025.102489_bib0010","doi-asserted-by":"crossref","first-page":"T39","DOI":"10.1530\/ERC-21-0118","article-title":"Second-generation hormonotherapy in prostate cancer and bone microenvironment","volume":"28","author":"Bouleftour","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"10.1016\/j.clgc.2025.102489_bib0011","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102489_bib0012","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2014.02.056","article-title":"Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)","volume":"66","author":"Rathkopf","year":"2014","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102489_bib0013","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clgc.2025.102489_bib0014","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.juro.2018.03.125","article-title":"Effect of abiraterone acetate and prednisone on prostate specific antigen and radiographic disease progression in patients with nonmetastatic castration resistant prostate cancer","volume":"200","author":"Ryan","year":"2018","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102489_bib0015","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.clgc.2025.102489_bib0016","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clgc.2025.102489_bib0017","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2016.03.017","article-title":"The PREVAIL Study: primary outcomes by site and extent of baseline disease for enzalutamide-treated men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer","volume":"70","author":"Evans","year":"2016","journal-title":"Eur Urol"},{"issue":"26","key":"10.1016\/j.clgc.2025.102489_bib0018","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.clgc.2025.102489_bib0019","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase iii study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102489_bib0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.clgc.2025.102489_bib0021","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clgc.2025.102489_bib0022","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.clgc.2025.102489_bib0023","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2025.102489_bib0024","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bju.12905","article-title":"Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer","volume":"116","author":"Ziehr","year":"2015","journal-title":"BJU Int"},{"issue":"11","key":"10.1016\/j.clgc.2025.102489_bib0025","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","article-title":"Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer","volume":"33","author":"O'Farrell","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102489_bib0026","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/pros.24096","article-title":"Risk of major adverse cardiovascular events among second-line hormonal therapy for metastatic castration-resistant prostate cancer: a real-world evidence study","volume":"81","author":"Liu","year":"2021","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.clgc.2025.102489_bib0027","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.urolonc.2020.08.003","article-title":"Androgen receptor inhibitor treatments: cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer","volume":"39","author":"Morgans","year":"2021","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102489_bib0028","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.euo.2023.01.001","article-title":"Adverse events and androgen receptor signaling inhibitors in the treatment of prostate cancer: a systematic review and multivariate network meta-analysis","volume":"6","author":"Cao","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102489_bib0029","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s11764-009-0114-1","article-title":"The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis","volume":"4","author":"Haseen","year":"2010","journal-title":"J Cancer Surviv"},{"issue":"1","key":"10.1016\/j.clgc.2025.102489_bib0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/pcan.2015.50","article-title":"Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer","volume":"19","author":"Mitsuzuka","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1016\/j.clgc.2025.102489_bib0031","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.21642","article-title":"Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy","volume":"106","author":"Basaria","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2025.102489_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117344","article-title":"Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"10","author":"Bosco","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.clgc.2025.102489_bib0033","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"24","key":"10.1016\/j.clgc.2025.102489_bib0034","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy","volume":"24","author":"Braga-Basaria","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102489_bib0035","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2022.04.034","article-title":"Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: a randomised clinical trial (HEAT)","volume":"171","author":"Ternov","year":"2022","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.clgc.2025.102489_bib0036","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1530\/ERC-16-0222","article-title":"Uncontrolled diabetes predicts poor response to novel antiandrogens","volume":"23","author":"Karantanos","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"19","key":"10.1016\/j.clgc.2025.102489_bib0037","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.3390\/cancers13194960","article-title":"Glutamine and cholesterol plasma levels and clinical outcomes of patients with metastatic castration-resistant prostate cancer treated with taxanes","volume":"13","author":"Mar\u00edn-Aguilera","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.clgc.2025.102489_bib0038","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2025.102489_bib0039","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clon.2004.10.009","article-title":"The utility of digital rectal examination after radical radiotherapy for prostate cancer","volume":"17","author":"Doneux","year":"2005","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"6","key":"10.1016\/j.clgc.2025.102489_bib0040","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.eururo.2005.07.006","article-title":"Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up","volume":"48","author":"Chaplin","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102489_bib0041","unstructured":"European Association of Urology (EAU). Prostate cancer. Available online: https:\/\/uroweb.org\/guidelines\/prostate-cancer\/chapter\/followup Accessed: July 20, 2024."},{"issue":"10","key":"10.1016\/j.clgc.2025.102489_bib0042","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"10231","key":"10.1016\/j.clgc.2025.102489_bib0043","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clgc.2025.102489_bib0044","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102489_bib0045","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.euf.2016.11.002","article-title":"68Ga-Labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography for prostate cancer: a systematic review and meta-analysis","volume":"4","author":"von Eyben","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"4","key":"10.1016\/j.clgc.2025.102489_bib0046","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.clgc.2025.102489_bib0047","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.3390\/cancers14082017","article-title":"Where do we stand in the management of oligometastatic prostate cancer? A comprehensive review","volume":"14","author":"G\u00f3mez Rivas","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.clgc.2025.102489_bib0048","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.clgc.2025.102489_bib0049","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102489_bib0050","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1016\/j.clgc.2019.12.010","article-title":"METastasis Reporting and Data System for prostate cancer as a prognostic imaging marker in castration-resistant prostate cancer","volume":"18","author":"Yoshida","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2025.102489_bib0051","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/jmri.27596","article-title":"Metastatic diffusion volume based on apparent diffusion coefficient as a prognostic factor in castration-resistant prostate cancer","volume":"54","author":"Yamamoto","year":"2021","journal-title":"J Magn Reson Imaging"},{"issue":"4","key":"10.1016\/j.clgc.2025.102489_bib0052","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.clgc.2025.102489_bib0053","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","article-title":"Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017","volume":"73","author":"Gillessen","year":"2018","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.clgc.2025.102489_bib0054","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2014.55.3875","article-title":"Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results","volume":"33","author":"Morris","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102489_bib0055","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/jamaoncol.2017.5808","article-title":"Radiographic progression-free survival as a clinically meaningful end point in metastatic castration-resistant prostate cancer: the PREVAIL randomized clinical trial","volume":"4","author":"Rathkopf","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2025.102489_bib0056","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2025.102489_bib0057","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2019.10.029","article-title":"Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials","volume":"125","author":"Robbrecht","year":"2020","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2025.102489_bib0058","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000943","article-title":"Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer","volume":"5","author":"Rao","year":"2020","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.clgc.2025.102489_bib0059","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/pcan.2016.71","article-title":"Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL","volume":"20","author":"Bryce","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.clgc.2025.102489_bib0060","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.euo.2020.07.001","article-title":"Patterns of cancer progression of metastatic hormone-sensitive prostate cancer in the ECOG3805 CHAARTED trial","volume":"3","author":"Bryce","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102489_bib0061","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","article-title":"METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer","volume":"71","author":"Padhani","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102489_bib0062","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40644-020-00350-x","article-title":"Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels","volume":"20","author":"Pricolo","year":"2020","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.clgc.2025.102489_bib0063","unstructured":"UroToday. APCCC 2022: Risk-adapted treatment monitoring in mCRPC. Available online: https:\/\/www.urotoday.com\/conference-highlights\/apccc-2022\/136836-apccc-2022-risk-adapted-treatment-monitoring-in-mcrpc.html (Accessed: June 20, 2024)."},{"issue":"4","key":"10.1016\/j.clgc.2025.102489_bib0064","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(22)00092-4","article-title":"Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial","volume":"23","author":"Dearnaley","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2025.102489_bib0065","first-page":"1651","article-title":"Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.clgc.2025.102489_bib0066","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s12885-018-4306-9","article-title":"Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial","volume":"18","author":"Dawson","year":"2018","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.clgc.2025.102489_bib0067","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1001\/jamaoncol.2021.3067","article-title":"Effects of exercise on cardiorespiratory fitness and biochemical progression in men with localized prostate cancer under active surveillance: the ERASE randomized clinical trial","volume":"7","author":"Kang","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102489_bib0068","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41391-019-0200-z","article-title":"Timing of exercise for muscle strength and physical function in men initiating ADT for prostate cancer","volume":"23","author":"Newton","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"10.1016\/j.clgc.2025.102489_bib0069","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002936","article-title":"Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial","volume":"16","author":"Bjerre","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.clgc.2025.102489_bib0070","doi-asserted-by":"crossref","DOI":"10.1097\/JS9.0000000000000982","article-title":"Impact of aerobic and resistance training on fatigue, quality of life, and physical activity in prostate cancer patients: a systematic review and meta-analysis","author":"Nader","year":"2024","journal-title":"Int J Surg"},{"issue":"Suppl_1","key":"10.1016\/j.clgc.2025.102489_bib0071","article-title":"Intense exercise for survival among men with metastatic prostate cancer: 12 months feasibility results from the INTERVAL-GAP4 trial. Abstract 81","volume":"9","author":"Newton","year":"2023","journal-title":"JCO Global Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102489_bib0072","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41391-022-00504-x","article-title":"Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth","volume":"25","author":"Kim","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.clgc.2025.102489_bib0073","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/bph.14778","article-title":"Mediterranean diet and health status: active ingredients and pharmacological mechanisms","volume":"177","author":"Schwingshackl","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102489_bib0074","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.clnu.2020.05.016","article-title":"Mediterranean-style dietary pattern improves cancer-related fatigue and quality of life in men with prostate cancer treated with androgen deprivation therapy: a pilot randomised control trial","volume":"40","author":"Baguley","year":"2021","journal-title":"Clin Nutr"},{"issue":"2","key":"10.1016\/j.clgc.2025.102489_bib0075","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/13685538.2018.1450854","article-title":"Adherence to Mediterranean diet and risk of prostate cancer","volume":"22","author":"Urquiza-Salvat","year":"2019","journal-title":"Aging Male"},{"issue":"4","key":"10.1016\/j.clgc.2025.102489_bib0076","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41443-018-0088-5","article-title":"Adherence to Mediterranean diet and prostate cancer risk in Sicily: population-based case-control study","volume":"31","author":"Russo","year":"2019","journal-title":"Int J Impot Res"},{"issue":"10","key":"10.1016\/j.clgc.2025.102489_bib0077","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1158\/1940-6207.CAPR-20-0236","article-title":"Inflammatory and insulinemic dietary patterns: influence on circulating biomarkers and prostate cancer risk","volume":"13","author":"Aroke","year":"2020","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"10.1016\/j.clgc.2025.102489_bib0078","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/01635581.2019.1621356","article-title":"Dietary glycemic index and glycemic load and the risk of prostate cancer: an updated systematic review and dose-response meta-analysis","volume":"72","author":"Sadeghi","year":"2020","journal-title":"Nutr Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2025.102489_bib0079","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/01635581.2018.1516787","article-title":"Association between dietary inflammatory index and the risk of prostate cancer: a meta-analysis","volume":"71","author":"Mohseni","year":"2019","journal-title":"Nutr Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2025.102489_bib0080","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/s41391-021-00342-3","article-title":"The effectiveness of psychological intervention for depression, anxiety, and distress in prostate cancer: a systematic review of literature","volume":"24","author":"Mundle","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"10.1016\/j.clgc.2025.102489_bib0081","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/pon.5749","article-title":"Mindfulness-based interventions for psychological wellbeing and quality of life in men with prostate cancer: a systematic review and meta-analysis","volume":"30","author":"Nnate","year":"2021","journal-title":"Psychooncology"},{"issue":"3","key":"10.1016\/j.clgc.2025.102489_bib0082","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41391-021-00470-w","article-title":"Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial","volume":"25","author":"Kaushik","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1016\/j.clgc.2025.102489_bib0083","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/1534735415617022","article-title":"Yoga intervention for patients with prostate cancer undergoing external beam radiation therapy: a pilot feasibility study","volume":"15","author":"Ben-Josef","year":"2016","journal-title":"Integr Cancer Ther"},{"issue":"3","key":"10.1016\/j.clgc.2025.102489_bib0084","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/01.ju.0000169487.49018.73","article-title":"Intensive lifestyle changes may affect the progression of prostate cancer","volume":"174","author":"Ornish","year":"2005","journal-title":"J Urol"},{"issue":"24","key":"10.1016\/j.clgc.2025.102489_bib0085","doi-asserted-by":"crossref","first-page":"8369","DOI":"10.1073\/pnas.0803080105","article-title":"Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention","volume":"105","author":"Ornish","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clgc.2025.102489_bib0086","series-title":"The Patient Experience Book. A Collection of the NHS Institute for Innovation and Improvement\u2019s Guidance Support","first-page":"19","year":"2023"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T20:29:44Z","timestamp":1771705784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1558767325001892"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102489","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integral Approach in the Follow-up of Prostate Cancer Patients: SOGUG Multidisciplinary Expert Panel Insights","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102489","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102489"}}